BOSTON, May 11, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2023, which ended April 1, 2023, are available on its Investor Relations website.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 11, 2023. The conference call and webcast can be accessed with the following information:
In addition, the Company has posted to its Investor Relations website the earnings release and analytical tables and supplemental information that will be referenced on its conference call and webcast, direct links to which are available below.
Direct link to 4Q FY23 Earnings Release: https://haemonetics.gcs-web.com/static-files/926b0cd9-052d-4f8b-8ea9-1d55bfae4a3c
Direct link to 4Q FY23 Analytical Tables and Supplemental Information: https://haemonetics.gcs-web.com/static-files/c556d6b4-2a16-49c2-a7e1-357cb54fa404
A replay of the conference call and webcast will be available for one year beginning on May 11, 2023, at 11:00 a.m. ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Sr. Director-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Media Contact: | |
Josh Gitelson, Director-Global Communications | |
(781) 356-9776 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$72.55 |
| Daily Change: | -0.90 -1.23 |
| Daily Volume: | 726,294 |
| Market Cap: | US$3.490B |
May 08, 2025 February 24, 2025 February 06, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
